Extended Data 6.
a. B16 frequency in mice untreated (
), or treated with BMDC loaded with intact B16 cells coated with alloIgG (
), or with intact B16 cells cross-linked to syngeneic IgG (
) (n=8). b. B16 tumor frequency in mice untreated () or treated with BMDC loaded with intact B16 cells coated with alloIgG () or with intact B16 coated with monoclonal IgG against MHC-I () (n=8). c. RMA tumor growth following inoculation with 2.5x105 tumor cells in naïve C57Bl/6 mice (), or in C57Bl/6 mice in which B16 tumors had completely regressed following treatment with alloIgG+TNFα+αCD40 (
). Also shown is the lack of B16 tumor growth in C57Bl/6 mice that were re-challenged with 2x105 B16 tumor cells following the regression of this tumor after treatment with alloIgG+TNFα+αCD40 (
) (n=8). d. Left: Tumor frequency in mice untreated () or treated with DC loaded with IC formed with alloIgG and cytosolic tumor proteins (
), nuclear tumor proteins (
) or membrane tumor proteins (). Right: Tumor frequency in mice untreated (), treated with DC loaded with IC formed from alloIgG and membrane proteins (), membrane proteins without O- and N-glycans (
), or heat-denatured membrane proteins (
) (n=5). e. B16 tumor growth in C57Bl/6 mice untreated (), or injected with TNFα+αCD40 (), TNFα+αCD40+alloIgG (), or TNFα+αCD40 and alloIgG absorbed on normal cells of the IgG-donor background (
) or on normal cells of the tumor background () (n=6). f. Tumor recurrence rates following resection in mice left untreated (), treated with 2x106 DC loaded with IgG-IC from conventionally-raised C57Bl/6 (), or with 2x106 DC loaded with IgG-IC from gnotobiotic C57Bl/6 mice (
) (n=6). Shown are the mean values ±SEM from two independent experiments. Asterisk (*) denotes p<0.05 and two asterisks (**) denote p<0.01.